

USSN: 09/622,104
Rsp. Dated July 8, 2004
Reply to Office Action of April 8, 2004
Page 2 of 3

REMARKS/ARGUMENTS

Claims 1-25 are pending. Claims 1-19 are under consideration. Claims 20-25 are withdrawn from consideration in response to a Restriction Requirement under 37 CFT 1.142(b).

Claims 1-6 are rejected under 35 U.S.C. 102(b) for allegedly being anticipated by Young et al. US Patent No. 5,376,638 (hereinafter "Young"). Applicants respectfully traverse this rejection.

Applicants have reviewed the sequences disclosed in the Young patent (SEQ ID NOs:1-28) and submit that none of the sequences are within the scope of the claimed invention. In particular with reference to particular sequences of the Young patent noted by the Patent Office:

SEQ ID NO:6 is equivalent to SEQ ID NO:15 of the instant application, which has specifically been excluded from the scope of the claims, see page 60, lines 7-8, of the application.

SEQ ID NO:7 has a sequence "LQTYPRTD" wherein a sequence of the claimed invention must have a sequence of "LQTYPRTN" and is, therefore, not within the scope of the claims.

SEQ ID NO:8 does not have an X₇ sequence that falls within the scope of the claims.

SEQ ID NO:9 does not have an X₁ sequence that falls within the scope of the claims.

SEQ ID NO:15 is equivalent to SEQ ID NO:16 of the instant application, which has specifically been excluded from the scope of the claims.

SEQ ID NO:24 does not have an X₁ sequence that falls within the scope of the claims.

SEQ ID NOs:25-28 are all equivalent to SEQ ID NO:16 of the instant application which has, as previously stated, been excluded from the scope of the claims.

Accordingly, Applicants submit that claims 1-6 are not anticipated by the Young patent. Applicants respectfully request reconsideration and withdrawal of the rejection of claims 1-6 based upon 35 U.S.C. 102(b).

Applicants note with appreciation that claims 7-19 have been found allowable with the only objection being their dependence upon a rejected base claim. However, in light of the

G:\LEGAL\PATENTS\256-153\256153.US\Rsp to OA 7-8-04.doc

USSN: 09/622,104
Rsp. Dated July 8, 2004
Reply to Office Action of April 8, 2004
Page 3 of 3

reasons provided above showing that the base claim should not be rejected, Applicants respectfully request reconsideration and withdrawal of the objection to claims 7-19.


Finally, Applicants respectfully request rejoinder of claims 20-25 pursuant to *In re Ochiai*, as the withdrawn method claims encompass all the limitations of the patentable composition claims.

CONCLUSION

Applicants respectfully submit that the claims are now in condition for allowance and request that a timely Notice of Allowance be issued in this case. The Examiner is encouraged to call the undersigned attorney to discuss any issues related to the prosecution of the instant application.

Applicants believe that no fee is necessitated by the present paper. However, in the event any fees are due or any amount is to be credited, Applicants authorize the Commissioner of Patents to debit or credit Deposit Account No. 010535.

Respectfully submitted,



Mi K. Kim
Reg. No. 44,830

AMYLIN PHARMACEUTICALS, INC.
9360 Towne Centre Drive
San Diego, CA 92121
Phone: (858) 552-2200
Facsimile: (858) 552-1936

G:\LEGAL\PATENTS\256-153\256153.US\Rsp to OA 7-8-04.doc